Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Redburn Partners Upgrades Morningstar to Buy

Redburn Partners Upgrades Morningstar to Buy

Redburn Partners analyst Russell Quelch upgrades Morningstar (NASDAQ:MORN) from Neutral to Buy.

byBenzinga Newsdesk

September 20, 2022

1 minute read

Redburn Partners analyst Russell Quelch upgrades Morningstar (NASDAQ:MORN) from Neutral to Buy.

Roth Capital Maintains Neutral on Tilray, Lowers Price Target to $4

By Benzinga Newsdesk

July 15, 6:52 AM

Roth Capital analyst Scott Fortune maintains Tilray (NASDAQ:TLRY) with a Neutral and lowers the price target from $8 to $4.

TLRY

Tesla Soared Over 25% In A Month: Options Market Weighs In On How Much Steam Is Left In Rally

By Bhavik Nair

June 5, 7:50 AM

Shares of Tesla Inc (NASDAQ:TSLA) have gained over 25% in the last month. CEO Elon Musk’s recent China…

TSLA

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

By Avi Kapoor

June 20, 5:29 AM

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday. Shares…

ARQT

Xencor Sells Portion Of Royalties And Milestones From Ultomiris And Monjuvi To OMERS Life Sciences For $215M

By Benzinga Newsdesk

November 7, 6:04 PM

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial

XNCR

Redburn Partners Upgrades Morningstar to Buy

Related Posts

Roth Capital Maintains Neutral on Tilray, Lowers Price Target to $4

Tesla Soared Over 25% In A Month: Options Market Weighs In On How Much Steam Is Left In Rally

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

Xencor Sells Portion Of Royalties And Milestones From Ultomiris And Monjuvi To OMERS Life Sciences For $215M